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Introduction
Casein (CAS) is an inexpensive, readily available, non-
toxic and highly stable milk protein. This protein is 
biocompatible, biodegradable and amphiphilic in nature 
and generally recognized as safe as natural food.1 The 
structural and physicochemical properties of CAS 
facilitate its functionality in drug delivery systems. These 
properties include binding of ions and small molecules, 
exceptional surface-active and stabilizing properties, 
excellent emulsification and self-assembly properties 
together with superb gelation and water binding 
capacities. CAS proteins have well defined hydrophobic 
and hydrophilic areas, which can self-assemble in the 
form of stable micelles in aqueous solutions.2-6 The 
strong association property of CAS is favorable for the 
nanoencapsulation processes. CAS-based nanoparticles 
are being recognized as potential delivery vehicles for 
nutraceuticals and pharmaceutical materials.7-11
Celecoxib (CLXB) is a non-steroidal anti-inflammatory 
drug that was recognized as a specific inhibitor of COX-
2 and approved by the United States Food and Drug 
Administration for the treatment of different types of 
joint inflammation and intense pain. In addition, it 
was recently approved as an oral adjunct to prevent 
colon cancer development in patients with familial 
adenomatous polyposis. It has been also investigated 
for its chemotherapeutic potential in the therapy of 
advanced cancers.12-14 According to Biopharmaceutical 
Classification System; CLXB is classified as a low solubility 
and high permeability drug (class II). The particle size of 
CLXB influences the content uniformity, dissolution and 
bioavailability of the product. The tmax of CLXB is about 
three hours after oral administration. Rapid onset of action 
is necessary to provide fast pain relief in the treatment 
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• Reassembled casein micelles
• Sodium caseinate
Abstract
Purpose: The objective of this work was to formulate casein (CAS) nanocarriers for the dissolution 
enhancement of poorly water soluble drug celecoxib (CLXB).
Methods: The CLXB loaded CAS nanocarriers viz., nanoparticles, reassembled CAS micelles 
and nanocapsules were prepared using sodium caseinate (SOD-CAS) as a carrier to enhance the 
solubility of CLXB. The prepared formulations were characterized for particle size, polydispersity 
index, zeta potential, percentage entrapment efficiency, and surface morphology for the selection 
of best formulation. Fourier transform infrared spectroscopy, differential scanning calorimetry 
and X-ray powder diffraction study was used to for the confirmation of encapsulation of CLXB. 
Further, in vitro drug dissolution, ex-vivo permeation studies on chicken ileum and stability 
studies were carried out.
Results: The CLXB loaded casein nanoparticles (CNP) (batch A2) showed a particle size diameter 
216.1 nm, polydispersity index 0.422 with percentage entrapment efficiency of 90.71% and 
zeta potential of -24.6 mV. Scanning electron microscopy of suspension confirmed globular 
shape of CNP. The in vitro release data of optimized batch followed non Fickian diffusion 
mechanism. The ex vivo permeation studies on chicken ileum of CLXB loaded CNP showed 
permeation through mucous membrane as compared to pure CLXB. The apparent permeability 
of best selected freeze dried CLXB loaded CNP (batch A2) was higher and gradually increased 
from 0.90 mg/cm2 after 10 min to a maximum of 1.95 mg/cm2 over the subsequent 90 min. A 
higher permeation was recorded at each time point than that of the pure CLXB.
Conclusion: The study explored the potential of CAS as a carrier for solubility enhancement of 
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of acute pain. Therefore, it is necessary to enhance the 
aqueous solubility and dissolution rate of CLXB to 
obtain faster onset of action, to minimize the variability 
in absorption and improve its overall oral bioavailability. 
This can be achieved by developing a nano-formulation of 
the CLXB.15,16
In this work, we propose an oral drug delivery system 
for CLXB based on the use of CAS, which has been 
well recognized as a promising biomaterial to develop 
nanocarriers for oral drug delivery. For this, nanoparticle, 
reassembled CAS micelles and CAS nanocapsules were 
synthesized to load CLXB to obtain a sustained drug 
release profile of CLXB. The prepared nanoformulations 
were characterized for particle size, polydispersity index, 
zeta potential, percentage entrapment efficiency, and 
surface morphology and in vitro drug dissolution. Ex-
vivo permeation study of was carried out on chicken 
ileum. Finally, the best selected formulation was evaluated 
for storage stability to understand the effect of storage 
conditions.
Materials and Methods 
Materials
CLXB was gifted by Aarti Drugs Ltd., Tarapur, India. 
Sodium caseinate (SOD-CAS) was gifted by Clarion Casein 
Ltd., North-Gujarat, India. Dialysis Membrane-110 was 
purchased from Himedia Laboratories Pvt. Ltd., Mumbai, 
India. Potassium phosphate, tri-potassium citrate, calcium 
chloride, sodium hydroxide, acetone, soya lecithin and 
sodium lauryl sulfate were purchased from Research-Lab 
Fine Chem Industries, Mumbai, India. All other reagents 
were of analytical grade and used as received.
Methods
Preparation of simulated intestinal fluid (SIF, USP, without 
pancreatin) with sodium lauryl sulphate (SIFSLS 1%)
Potassium dihydrogen phosphate (6.805 g), sodium 
hydroxide (0.896 g) and sodium lauryl sulfate (10 g) were 
dissolving in sufficient amount of deionized water to 
produce 1000 mL of 1% SIFSLS. This solution was further 
used as a release medium.17
Solubility studies
Solubility was determined by placing ≈50 mg of CLXB in 
5 mL each of distilled water, 1% SIFSLS, phosphate buffers 
(pH 6.8). Solutions were stirred using a magnetic stirrer 
(REMI Motors, Mumbai, India) at 200 rpm for 24 h. The 
temperature was maintained at 25 °C. The solutions were 
filtered through Whatman filter paper No. 41 and the 
CLXB concentration was determined using UV-visible 
spectrophotometer (JascoV-730, Tokyo, Japan) at 254 
nm.18
Determination of critical micelle concentration (CMC) 
by conductometry technique
CMC of SOD-CAS was determined as per the reported 
method.19,20 The conductivity was measured using a digital 
conductometer (Systronics 306, Ahmedabad, India) with 
conductivity cell (Systronics, Type CD-10, Ahmedabad, 
India) having platinized electrode with a cell constant 
of 0.1 to 5.0. All the solutions were prepared in distilled 
water with different SOD-CAS concentrations. The 
solutions were stirred for 1 min prior to the conductivity 
measurement. The conductivity meter was calibrated using 
standard KCl solution. The accuracy of the conductivity 
meter was 0.01 µS/cm during the study. The plot SOD-
CAS concentration v/s K (conductivity) was checked for 
linear increase in readings upon addition of SOD-CAS.19,20
Preparation of CLXB loaded CAS carriers
Three methods were used to load CLXB into the carrier 
CAS, viz., nanoparticle preparation, reassembled CAS 
micelles and CAS nanocapsules.
Preparation of casein nanoparticles (CNP)
Solutions of SOD-CAS (0.5%, 1% and 1.5% w/v) were 
prepared in distilled water by stirring. CLXB ethanolic 
solution (0.8 mL) containing 50 mg of CLXB was added 
to each 40 mL of the prepared SOD-CAS solutions. The 
solution was stirred for 1 h to achieve effective CLXB-
SOD-CAS binding. Further, 0.5 mL CaCl2 solution (1M) 
was added to this solution. The formed slightly turbid 
solution was stirred for 30 min. The solutions were 
centrifuged at 2700 rpm (R-8C, REMI Motors, Mumbai, 
India) for 10 min to remove the bigger microparticles. 
Ethanol was removed from the supernatant using a 
vacuum flash evaporator (ROTAVAP, PBCT-8D, Superfit, 
India). Supernatant containing nanoparticles was used 
for further studies. Final CLXB concentration was 1.25 
mg/mL.21 Due to the addition of CaCl2 solution, calcium 
ions initiate the protein chain rearrangement and the 
soluble CAS present in the solution turns into the micellar 
framework and helps in formation of dense nanoparticles.
Preparation of re-assembled casein micelles (r-CM)
CLXB (50 mg) dissolved in 0.8 mL ethanol was slowly 
added to 20 mL each of 1%, 2%, 3% w/w SOD-CAS 
solutions with vigorously stirring. After stirring for 5 min, 
0.4 mL of 0.4 M tripotassium citrate, 2.4 mL of 0.08 M 
dipotassium phosphate (K2HPO4) and 2 mL of 0.08 M 
calcium chloride (CaCl2) were added. Eight additions 
of 0.24 mL 0.08 M K2HPO4 and 0.50 mL 0.08 M CaCl2 
were made at 15 min intervals. The pH was maintained 
between 6.7 and 7.0 with 0.1 N HCl or 1 N NaOH. The 
CLXB-Caseinate solution was constantly stirred. The final 
volume was adjusted to 40 mL with distilled water, titrated 
to a final pH of 6.7 with 0.1 N HCl. The final solutions 
were further stirred (R-8C, REMI Motors, Mumbai, India) 
for 1 h to obtain the micellar solutions. Final SOD-CAS 
concentration was 0.5% (B1), 1% (B2) and 1.5% (B3). The 
CLXB concentration in each solution was 1.25 mg/mL.22 
The solvents were eliminated from the suspension using a 
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vacuum flash evaporator (PBCT-8D, ROTAVAP, Superfit, 
India).
Preparation of casein nanocapsules (CNC) using soya 
lecithin
For preparing nanocapsules, the organic phase was formed 
by dissolving 400 mg of soya lecithin and 50 mg CLXB in 
0.8 mL of ethanol, followed by the addition of 0.20 mL 
of Labrasol and 12.0 mL of acetone. This organic phase 
was immediately poured over 25 mL each of 0.5% (C1), 
1% (C2) and 1.5% (C3) w/v SOD-CAS solutions in 10 
mM phosphate buffer (pH 7.4) to obtain the nanocapsule 
suspension. The solvents were eliminated from the 
suspension using a vacuum flash evaporator (PBCT-8D, 
ROTAVAP, Superfit, India). The final volume was 40 mL 
and CLXB concentration in each solution was 1.25 mg/
mL.23
Evaluation of the CAS formulations
Entrapment efficiency and drug loading
To 5 mL of each of the prepared formulations, 5 mL 
SIFSLS 1% was added in a 10 mL test tube. The aqueous 
suspension was sonicated in a probe ultrasonicator (Oscar 
Ultra Sonics, Mumbai, India) for 5 min. The formulations 
containing CLXB were separated from unentrapped 
CLXB by centrifugation (R-8C, REMI Motors, Mumbai, 
India) at 9000 rpm for 25 min. The supernatant was 
recovered and assayed spectrophotometrically using a UV 
spectrophotometer (V-730, Jasco, Tokyo, Japan) at 254 nm 
against SIFSLS 1% solution. CLXB concentrations for total 
and non-encapsulated CLXB samples were estimated. The 
drug entrapment efficiency was calculated using following 
equation.24,25
The drug loading was determined by centrifugation of 10 
mL of formulation at 9000 rpm for 25 min. The unloaded 
CLXB in the supernatant obtained after centrifugation 
(R-12C, REMI Motors, Mumbai, India) of all the batches 
was determined using UV spectrophotometer (V-730, 
Jasco, Tokyo, Japan) at 254 nm against SIFSLS 1% solution. 
Percent drug loading for each batch was calculated using 
following equation.26
Measurement of particle size and zeta (ζ) - potential 
The zeta (ζ) - potentials and the mean particle size of 
the CAS aggregates were determined by Zetasizer (v2.3, 
Malvern Instruments Ltd., Mumbai, India). Measurements 
were carried out at 25 °C in triplicate.27
In vitro release studies
The formulation (10 mL) was filled into pre-swollen 
dialysis bags-110 LA 395-1MT (length: 7 cm, molecular 
weight cut off: 1200-14 000 Dalton (Himedia Laboratories 
Pvt. Ltd., Mumbai, India) for in vitro release studies using 
USP type-II apparatus (LABINDIA, DS 8000, India). The 
release studies were carried out at 50 rpm using 400 mL of 
SIFSLS 1% as dissolution medium.28,29 The temperature of 
the release medium was maintained at 37±0.5ºC. Aliquots 
(2 mL) were withdrawn at every 10, 20, 30, 40, 50, 60, 90, 
120 min and filtered. The same volume was replaced with 
fresh medium maintained at similar temperature. The 
same procedure was followed for 10 mL saturated solution 
of CLXB. The absorbance of filtrate was measured by UV 
spectrophotometric method (V-730, Jasco, Tokyo, Japan) 
at 254 nm to estimate CLXB concentration.30-32 All the 
measurements were carried out in triplicate.
Lyophilization 
Prepared CNP (batch A2 solution) was frozen by freezing 
in ultra-low freezer (Panasonic, MDF-U55V-PE ULT 
model, Japan) at -81°C for 24 h and further lyophilized 
(Labconco, Free Zone 2.5 plus, Missouri, USA). The 
solutions were freeze dried without any adjuvants. The 
samples (100 mL) were dispensed in 250 mL semi-
stoppered glass beaker and minimum temperature of 
the lyophilization chamber was maintained at -82°C. 
Sublimation lasted 48 h at a vacuum pressure of 0.090 
mBar without heating, while maintaining condenser 
surface temperature at -82°C.33
Determination of surface morphology
Solution of CNP (batch A2) and its freeze dried powder 
were examined under a scanning electron microscope 
(SEM) (Carl Zeiss AG, Oberkochen, Germany) to study 
the particle surface morphology and shape. Samples were 
spread over a slab and dried under vacuum. Micrographs 
were taken using Supra 5 SEM at an accelerating voltage 
of 10 kV.34-36
Preparation of physical mixture
CLXB and SOD-CAS were passed through a sieve # 100 
and the physical mixture (PM) was prepared by mixing 
pre-weighed amount of CLXB with SOD-CAS at a 1:1 
ratio.34
Fourier-transform infrared study
The Fourier-transform infrared spectra (FTIR) of CLXB, 
SOD-CAS, PM and freeze dried CNP (batch A2) were 
recorded over a range of 4000–600 cm-1 to study the 
principal peaks FTIR spectrophotometer (Alpha T, 
Bruker, Germany) by attenuated total reflection (ATR) 
method. Processing the FTIR spectrophotometric data 
Entrapment efficiency (%) = 
Total drug added − unentrapped drug
Total drug added × 100 
 
Drug loading (%) = 
Total drug added − unentrapped drug (mg)
 Total drug added (mg) + Total excipients added (mg) × 100 
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was done using OPUS Version - 7.5 software.37
X-ray powder diffraction
The X-ray powder diffraction (XRPD) spectra of CLXB, 
PM and freeze dried CNP (batch A2) were recorded using 
a Smart Lab high power powder X-ray diffractometer 
(Rigaku Corp., Tokyo, Japan) with Cu as a target filter, a 
voltage/current of 40 kV/40 mA and a scan speed of 4º/
min. The samples were analyzed at a 2θ angle range from 
10° to 89°. The step time was 0.5 s and the acquisition time 
was 1 h.24
Differential scanning calorimetry
The samples of CLXB, SOD-CAS, freeze dried CNP (batch 
A2) and PM were placed in sealed aluminium pans and 
heated at 10°C/min under a nitrogen atmosphere (flow 
rate 20 mL/min) in the range of 30-300ºC. Thermograms 
were recorded using differential scanning calorimeter 
(4000, Perkin Elmer, Massachusetts, United States). 
Processing of the calorimetric data was done using PYRIS 
version - 11.1 software.38 
Ex-vivo permeation study
The everted gut sac method was used to determine the 
apparent permeability of pure CLXB and freeze dried 
CNP (batch A2).39,40 The intestine used was of male 
White Leghorn chicks weighing between 800 and 1000 
g and was bought from a local slaughter house within 
30 min of slaughter. By rinsing intestine with a pH 7.4 
buffer solution (Krebs–Ringer solution) the lumen 
was thoroughly removed from the mucus. The ileum 
bag was cut into equal segments of 6.9 cm length each, 
flushed with normal saline to remove the contents, and 
then immersed in SIFSLS 1% solution. Each segment was 
inverted by gently pushing a notched glass rod through 
the whole length of the intestine and then filled with 1 mL 
of Krebs solution.41 Both ends of each segment were tied 
with a thread forming an everted ileum bag. Each bag was 
immersed in 400 mL SIFSLS 1% solution containing CLXB 
(12.5 mg) or CLXB loaded CNP equivalent to 12.5 mg 
at 37°C (outer compartment). Samples were withdrawn 
at predetermined time intervals for 90 min from inside 
of the sac. The concentration of CLXB permeated was 
determined by measuring its absorbance using a UV 
spectrophotometer at 254 nm and the following equation 
was used to calculate the apparent permeability.42-44
To calculate the surface area (A) of mucus membrane, 
the intestine was considered a cylinder and the following 
equation was used:
A(cm2) = 2πrh + 2πr2
Therefore, the surface area (A) of mucous membrane 
was 11.61 cm2 and the concentration of the CLXB in 
the donor compartment was 0.125 mg/ml. The linear 
regression analysis of plot of drug permeated (µg) vs. time 
(min) was used to obtain the slopes for determining flux.
Comparative in-vitro dissolution studies 
The freeze dried CNP (batch A2) (510 mg) equivalent 
to 100 mg CLXB was filled in hard gelatin capsule shell, 
size 0 (Qualicaps Inc., Japan). The dissolution rate of the 
pure CLXB, filled CNP capsule and Zycel-100 capsule 
(Zydus Healthcare Limited, India) was determined using 
USP type-II apparatus (DS 8000, LABINDIA, India) at 50 
rpm using 900 mL of SIFSLS 1%. The temperature of the 
dissolution medium was maintained at 37±0.5°C. Aliquots 
(5 mL) were withdrawn at 10, 20, 30, 40, 50, 60, 90 and 
120 min intervals, filtered and the absorbance of filtered 
sample solution was measured by UV spectrophotometric 
method (Jasco, Tokyo, Japan, model V-730) at 254 nm. 
All the measurements were carried out in triplicate. The 
concentration of CLXB was determined from the standard 
calibration curve.
Analysis of drug release kinetics
To determine the drug release kinetics, the drug release 
data of CNP (A2 formulation) was analyzed for zero order 
and first order kinetic equations. Further, to confirm the 
drug release mechanism, the data was analyzed according 
to the Higuchi, Hixson-Crowell and Korsmeyer’s-Peppas’ 
models. Kinetic analyses were performed using PCP-
Disso-v3 software.
Stability testing
Stability studies were carried out according to the ICH 
Q1A (R2) guidelines at different storage temperature and 
RH conditions (40 ± 2°C and 75 ± 5% RH) and (25 ± 2°C 
and 60 ± 5% RH) on freeze dried CNP batch A2 using 
triple stability chamber (Thermolab, Mumbai, India). The 
product was kept in petri plate. The samples were taken at 
predetermined time interval (15, 30, 45, 60 and 90 days) 
to determine the appearance, texture and percentage drug 
content.37 For the estimation of percentage drug content, 
accurately weighed (10 mg) of CNP formulation was 
dispersed into 25 ml of SIFSLS 1%. The prepared mixture 
was shaken for 24 h. After 24 h, the solution was filtered, 
and the filtrate was analyzed for drug content by a UV 
spectrophotometer (V-730, Jasco, Tokyo, Japan) at 254 nm 
after suitable dilution. The drug content was determined 
using equation: y = mx ± c, where y is the absorbance, m 
is slope, x is drug amount, and c is the intercept. Slope and 
intercept values were taken from the calibration curve. 
Results and Discussion 
Solubility studies
The solubility of CLXB as observed in distilled water, 
SIFSLS 1% and phosphate buffer (pH 6.8) (Table 1). The 
Apparent Permeability ( mgcm2) = 
Amount of CLXB permeated (mg) × Volume
Surface area of mucous membrane  
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results indicated that the highest solubility of CLXB was 
in SIFSLS 1% and poor solubility was observed in distilled 
water.
Critical micelle concentration (CMC)
Conductivity measurements were used to determine 
CMC of the negatively charged SOD-CAS. Figure 1 shows 
the results of conductivity measurements of SOD-CAS 
solutions. Initially, the conductivity increased linearly 
upon addition of SOD-CAS due to the increased amount 
of dissolved anions and cations of SOD-CAS. Above the 
CMC, SOD-CAS micelles were formed (Table 1). The rate 
of increase in conductivity was decreased with further 
addition of SOD-CAS. Thus, a smaller slope value was 
noticed above the CMC.20 Hence, the CMC was found in 
the range of 0.05-0.22 mg/mL.42 All further formulations 
were prepared using SOD-CAS concentrations above its 
CMC.
Evaluation of CAS formulations
Entrapment efficiency and drug loading
The percentage entrapment efficiency and drug loading 
in all nine formulations were calculated (Table 2). It is 
evident that amongst all formulations, the entrapment 
efficiency and drug loading were highest in CNP batches 
as compared to CNC and r-CM. At a concentration of 1% 
SOD-CAS (batch A2) CNP showed highest entrapment 
efficiency of 90.71±0.01%.
Particle size and zeta (ζ) - potential
The particle size of different CNP, r-CM and CNC 
formulations was found to be in the range between 216.3 
Table 1. Results of celecoxib solubility in different solvents and conductometric 
titration study to determine critical micelle concentration of sodium caseinate
Solubility of celecoxib
Solvent Solubility (µg/mL)
Water 6.10 ± 0.033
SIFSLS 1% 240.52 ± 0.098
Phosphate buffer (pH 6.8) 12.01 ± 0.026
Conductometric titration













Figure 1. Change of conductivity with increasing SOD-CAS concentration.
nm to 665.1 nm (Table 2). The zeta potential of different 
CNP, r-CM and CNC batches was found to be -23.8 mV to 
- 32.2 mV (Table 2) indicating a good colloidal stability.45 
This negative charge is a result of the net electrostatic 
charge on the CAS surface at pH 7.4, which is above 
its isoelectric point, where the CAS carboxylic groups 
become negatively charged.
In vitro drug release
In vitro drug release studies were carried out in SIFSLS 1%. 
Results of in vitro drug release studies are shown in Table 
2. The results show that 17.03% of pure CLXB was released 
from CNP in 120 min (Figure 2a), suggesting a strong 
need to enhance the dissolution of CLXB. The presence 
of SOD-CAS increases the dissolution rate of CLXB up to 
a drug-excipient ratio of 1:1. Factors such as the lack of 
crystalline form (supported by XRD results), the increased 
surface area of the drug, and the hydrophilic surface of 
SOD-CAS helped to improve the dissolution of CLXB. 
The highest percentage cumulative release was observed 
from CNP batches (Table 2 and Figure 2a). Percentage 
cumulative release for CNC was found to be poor, this 
might be due to the formation of a viscous boundary 
layer around the CLXB particles, leading to increase in 
diffusion path length and decrease in the dissolution rate 
(Table 2 and Figure 2b). The r-CM formulations showed 
higher percentage cumulative drug release as compared 
to CNC batches. The highest percentage cumulative 
release was 89% at 1% concentration of SOD-CAS. 
From the results obtained, it is evident that amongst all 
formulations the onset of dissolution of CNP batches was 
higher as compared to CNC and r-CM (Figure 2c). At a 
concentration of 1% SOD-CAS (CNP batch A2), highest 
release of 98% was achieved.
Lyophilization
CAS nanoparticles are not stable in aqueous form, 
therefore; we examined the ability to form a freeze-
dried powder having a much better stability profile. No 
additives are needed for efficient lyophilization as it has 
been reported that CAS itself acts as a cryoprotectant.33 By 
lyophilization, without any additives, we are able to keep 
the CNP nanoparticles (batch A2) stable in a dry powder 
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form for at least 3 months. After freeze-drying of the 
nanoparticles and re-suspending dried powder in SIFSLS 
1% of the original concentration, transparent solutions 
were formed, that resemble very much the original 
suspension.34
Surface morphology
The SEM of the suspension (CNP batch A2) helps in 
concluding that the formed nanoparticles are globular, 
uniform in size and well separated (Figure 3a). In the 
micrograph of freeze dried powder CNP, the original 
morphology of the raw materials disappeared, and it was 
not possible to differentiate the two components (Figure 
3b). The freeze dried samples appeared as agglomerates. 
The amorphous form of the freeze dried sample was 
indicative of the presence of a new solid phase, leading to 
estimate the existence of a single phase.46
Fourier-transform infrared study
The physical mixture was prepared to check for possible 
interactions between CLXB and SOD-CAS. In the FTIR 
spectrum of CLXB, the medium absorption bands at 3160 
cm-1 and 3260 cm-1 are assigned to -NH symmetric and 
asymmetric stretching vibrations, respectively (Figure 
4a). The other characteristic bands are attributed to: 
1150 and 1343 cm-1 (S=O symmetric and asymmetric 
stretching, respectively), 1532 cm-1 (NH bend), 3222 cm-1 
(NH2 stretching) and 838 cm
–1 (CH bend).47 The FTIR 
spectrum of PM showed compatibility of drug CLXB with 
CAS (Figure 4b). The spectrum of SOD-CAS showed 
important bands at 1159 cm-1 (C-O stretch), 903-074 
cm-1 (C-H bend) and 1844 cm-1 (C=O) (Figure 4c). The 
softening of peaks in the spectrum of freeze dried CNP 
indicated the encapsulation of CLXB in CNP (Figure 4d).
X-ray powder diffraction (XRPD)
XRPD studies were carried out for further characterization 
Table 2. Evaluation of casein nanocarriers
Batch Entrapment Efficiency (%) Drug Loading (%) Particle size (nm) Zeta Potential (mV) Polydispersity index
Cumulative release (%) 
(120 min)
Casein nanoparticles (CNP)
A1 (0.5%) 72.08±1.2 25.02±0.28 259.06±1 -23.6±0.1 0.436±0.001 78.57±0.7
A2 (1%) 90.71±3.1 14.08±0.16 216.1±2 -24.6±0.1 0.422±0.001 98.17±1.3
A3 (1.5%) 82.26±2.3 10.02±0.14 222.53±4 -24.5±0.1 0.371±0.002 92.84±1.4
re-assembled casein micelles (r-CM)
B1 (0.5%) 72.05±1.2 15.21±0.17 631.8±7 -29.3±0.1 0.786±0.001 76.34±0.6
B2 (1%) 90.65±3.4 9.44±0.12 665.3±6 -28.9±0.5 0.587±0.001 89.24±1.5
B3 (1.5%) 81.14±2.1 6.84±0.11 643.6±8 -29.5±0.1 0.625±0.002 82.40±0.6
Casein nanocapsules (CNC)
C1 (0.5%) 72.03±1.4 8.54±0.12 394.6±5 -32.3±0.1 0.197±0.002 11.85±0.9
C2 (1%) 90.52±3.2 6.94±0.11 389.2±3 -29.5±0.1 0.191±0.001 18.31±1.1
C3 (1.5%) 80.15±2.4 5.85±0.10 396.4±4 -30.5±0.1 0.262±0.001 13.50±0.6
Figure 2. In vitro release profile of Celecoxib from CNP (a), CNC (b), and 
r-CM (c) by dialysis bag method in 400 mL of SIFSLS 1% at 50 rpm and 
37±0.5C using USP type-II apparatus. Data presents mean ± SD (n = 3).
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of solid states of the samples. The patterns obtained for 
pure CLXB, PM and lyophilized powder of CNP (batch 
A2) are depicted in Figure 5 (top panel). The characteristic 
diffraction peaks were observed at 2θ values of 10.74°, 
14.85°, 16.14°, 22.16°, 27.02°, and 30.38° correspond to the 
powder diffraction pattern for pure CLXB. The crystalline 
state of CLXB in the physical mixture of SOD-CAS and 
CLXB is evident from the characteristic diffraction peaks. 
However, the XRPD pattern in the lyophilized powder of 
CNP suggests the amorphous structure of CLXB within 
the formulation. These XRPD results are compatible with 
the DSC observations.
Differential scanning calorimetry
DSC thermograms and data of pure CLXB, PM, SOD-
CAS, and CNP (batch A2) are shown in Figure 5 
(bottom panel). Thermogram of CLXB exhibited a 
sharp endothermic peak at 163.42°C, (ΔH = 131.2 J/g), 
Tm corresponding to its melting point,48,49 indicating 
crystalline nature of CLXB. Thermogram of PM showed 
the endothermic peak of CLXB but with a slight shift to 
lower Tm (163.02°C, at ΔH = 81.06 J/g) that does not seem 
to be significant indicating compatibility between CLXB 
and SOD-CAS. Thermogram of SOD-CAS showed no 
peak, indicating the amorphous nature of SOD-CAS. The 
lyophilized powder showed a smooth thermal curve and 
indicating amorphous nature of CLXB. The DSC results 
confirm the encapsulation of CLXB in nanoparticles. 
The amorphous property of CLXB in the prepared 
nanoparticles containing SOD-CAS is responsible for the 
dissolution enhancement.48
Ex-vivo permeation study
Oral bioavailability is maximum for the drugs having 
optimum permeability and solubility.38 It is indispensable 
to examine permeation through the mucous membrane 
to know not only the diffused amount of CLXB, but also 
to verify whether the release mechanism is influenced by 
the solubility. It has been reported that the chicken small 
intestine could be a useful model in permeation studies.40 
In the present study, the permeation studies were carried 
out for pure CLXB and optimized CNP formulation 
(batch A2).
The apparent permeability for both the pure CLXB and 
the freeze dried CNP powder followed a similar pattern 
over time (Figure 6). The apparent permeability of the 
pure CLXB gradually increased from 0.014 mg/cm2 after 
a period of 10 min to a maximum of 0.48 mg/cm2 over 
the subsequent 90 min. Compared to the pure CLXB, the 
apparent permeability of freeze dried CNP was higher and 
gradually increased from 0.90 mg/cm2 after 10 min to a 
maximum of 1.95 mg/cm2 over the subsequent 90 min. The 
gradient of the graph of freeze dried CNP was higher than 
that of the pure CLXB. A higher permeation was recorded 
at each time point than that of the pure CLXB (Table 3). 
Nanoparticles solubilize CLXB in the outer compartment, 
Figure 3. Scanning electron micrograph of CNP suspension (batch A2) (a) and 
freeze dried CNP (batch A2) (b). Scales are given on individual micrograph.
Figure 4. Fourier transform-infrared spectra of CLXB (a), physical mixture of 
CLXB and SOD-CAS (b), SOD-CAS (c), and freeze dried CNP batch A2 (d).
Figure 5. XRD spectrum (top panel): pure Celecoxib (a), physical mixture of 
CLXB and SOD-CAS (b), freeze dried powder CNP (c), and DSC thermograms 
(bottom panel): pure CLXB (a), physical mixture of CLXB and SOD-CAS (b), 
SOD-CAS (c), and CNP (d).
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thereby maintaining/increasing the driving force for 
permeation. This indicated the permeation enhancing 
potential of molecularly dissolved and solubilized CLXB 
in the SOD-CAS nanoparticles.
Comparative in-vitro dissolution studies
Comparative in vitro dissolution profiles of pure CLXB, 
freeze dried CNP (batch A2) filled in hard gelatin capsule 
and reference formulation (Zycel-100) are presented in 
Figure 6. The cumulative percentage drug release from 
the freeze dried CNP and Zycel-100 capsule was 98.83 
Figure 6. Top panel: comparative apparent permeability of Celecoxib from 
pure Celecoxib and freeze dried CNP (batch A2) by everted gut sac method 
in in SIFSLS 1% solution. Bottom panel: comparative in vitro release profile 
of CLXB from pure CLXB, marketed formulation and freeze dried CNP (batch 
A2) by dialysis bag method in 900 mL of SIFSLS 1% at 50 rpm and 37 ± 0.5 
°C using USP type-II apparatus. Data presents mean ± SD (n = 3).




Celecoxib Formulation CNP (batch A2)
Cumulative amount of 
Celecoxib permeated (%)
14.7 63.85
J (µg/cm2/h) 1.81 3.67
Table 4. Results of stability testing of freeze dried CNP (batch A2) analysis after 90 days study
Parameters
40 ± 2ºC & 75 ± 5% RH 25 ± 2ºC & 60 ± 5% RH
Initial After 90 days Initial After 90 days
Drug content (%) 100 ± 0.01 90.56 ± 0.01 100 ± 0.01 90.40 ± 0.01
Appearance Transparent solution Transparent solution Transparent solution Transparent solution
and 90.05%, respectively after 120 min. The pure CLXB 
showed only 17.03% of release after a period of 120 min. 
It is evident that capsule containing freeze dried CNP had 
improved dissolution rate of CLXB.
Drug release kinetics
The highest correlation coefficient serves as an indicator of 
the best fit for each of the models considered. The value of 
n is about 0.45 for a Fickian release, and for an anomalous 
or non-Fickian release the release is mainly by diffusion 
with n values > 0.45 and < 1.0. In the present study, the 
highest correlation coefficient (r2) for Korsmeyer’s-
Peppas’ model was 0.9989 and this was the best fit model. 
The value of release exponent (n) and release rate constant 
(k) for best fit model were 0.6865 and 0.1770, respectively. 
It indicated coupling of diffusion and erosion mechanism 
- so-called anomalous diffusion. This indicated that the 
drug release was controlled by more than one process. 
Thus, the in vitro release data of optimized batch CNP 
(batch A2) followed non Fickian diffusion mechanism. 
This kind of release behavior could be explained due to 
the erosion or relaxation of casein nanoparticle matrix 
that would favor drug diffusion. A similar explanation has 
been proposed for the release of resveratrol from CNP.50 
Similar release behavior of resveratrol from zein based-
nanoparticles has been reported earlier.51
Stability testing 
The lyophilized freeze dried CNP formulation (batch A2) 
was examined in order to get an idea of any possibility of 
drug degradation during storage. The results of stability 
study of various formulations under different conditions 
are presented in Table 4. As time increased, the drug 
content decreased in 3 months to 90% under both the 
study conditions. However, no significant difference in 
the physical appearance was observed after a period of 3 
months. 
Conclusion
The SOD-CAS based nanoparticles had spherical 
shape and uniform size. CLXB-loaded CNP enhanced 
the dissolution rate of CLXB as compared to both 
reference product and pure CLXB. The CAS seems to 
be an appropriate and effective carrier for solubility 
enhancement of CLXB. The study concludes that the 
nanometric particles can be freeze-dried without any 
cryoprotectant and when re-suspended their structural 
characteristics are well preserved.
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